Abstract: This invention provides antibodies that interact with or bind to human nerve growth factor (NGF) and neutralize the function of NGF thereby. The invention also provides pharmaceutical compositions of these antibodies and methods for neutralizing NGF function, and particularly for treating NGF-related disorders (e.g., chronic pain) by administering a pharmaceutically effective amount of anti-NGF antibodies. Methods of detecting the amount of NGF in a sample using anti-NGF antibodies are also provided.
Type:
Grant
Filed:
October 9, 2009
Date of Patent:
February 16, 2016
Assignees:
Amgen Inc., E. R. Squibb & Sons, L.L.C.
Inventors:
Kenneth D. Wild, Jr., James J.S. Treanor, Haichun Huang, Heather Inoue, Tie J. Zhang, Frank Martin
Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
Abstract: The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host animal. The presence of immunoglobulin constant regions of the host animal allows for generation of improved antibodies in such transgenic host animals. Subsequently, the chimeric antibodies can be readily converted to fully human antibodies using recombinant DNA techniques. Thus, the invention provides compositions and methods for generating human antibodies in which chimeric antibodies raised in vivo in transgenic mice are used as intermediates and then converted to fully human antibodies in vitro.
Type:
Grant
Filed:
July 2, 2012
Date of Patent:
December 29, 2015
Assignee:
E. R. SQUIBB & SONS, L.L.C.
Inventors:
Dawn M. Tanamachi, Peter Brams, Amelia Black
Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
Type:
Grant
Filed:
November 14, 2013
Date of Patent:
December 22, 2015
Assignees:
UNIVERSITY OF MASSACHUSETTS, E. R. SQUIBB & SONS, L.L.C.
Inventors:
Donna M. Ambrosino, Gregory J. Babcock, Teresa Broering, Robert Graziano, Hector Javier Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William D. Thomas, Jr., Hui-Fen Zhang
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Glypican-3 with high affinity. Nucleic acid molecules encoding Glypican-3 antibodies, expression vectors, host cells and methods for expressing the Glypican-3 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the Glypican-3 antibodies are also provided. Methods for detecting Glypican-3, as well as methods for treating various Glypican-3-related conditions, including hepatocellular cancer, are disclosed.
Type:
Grant
Filed:
February 10, 2014
Date of Patent:
December 22, 2015
Assignee:
E. R. SQUIBB & SONS, L.L.C.
Inventors:
Jonathan Alexander Terrett, Li-Sheng Lu, Haichun Huang, Dapeng Yao, Chin Pan, Heidi N. LeBlanc, Tim W. Sproul, Mark Yamanaka
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.
Type:
Grant
Filed:
January 22, 2013
Date of Patent:
September 22, 2015
Assignee:
E. R. Squibb & Sons, L.L.C.
Inventors:
Cynthia A. Vistica, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PTK7 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PTK7, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PTK7 antibodies.
Type:
Grant
Filed:
May 10, 2012
Date of Patent:
August 11, 2015
Assignee:
E. R. Squibb & Sons, L.L.C.
Inventors:
Jonathan Alexander Terrett, Li-Sheng Lu, Chin Pan
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
Type:
Grant
Filed:
January 22, 2013
Date of Patent:
August 11, 2015
Assignee:
E. R. SQUIBB & SONS, L. L. C.
Inventors:
Alan J. Korman, Mark J. Selby, Changyu Wang, Mohan Srinivasan, David B. Passmore, Haichun Huang, Haibin Chen
Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Type:
Grant
Filed:
November 18, 2014
Date of Patent:
July 21, 2015
Assignees:
E.R. SQUIBB & SONS, L.L.C., Ono Pharmaceutical Co., LTD.
Inventors:
Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Selby, Bingliang Chen, Josephine M. Cardarelli, Haichun Huang
Abstract: This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-?) and methods for treating IFN-? mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-?. Methods of detecting the amount of IFN-? in a sample using antibodies to IFN-? are also provided.
Type:
Grant
Filed:
August 13, 2013
Date of Patent:
December 9, 2014
Assignees:
Amgen Inc., E.R. Squibb & Sons, L.L.C.
Inventors:
Andrew A. Welcher, Hilary T. Chute, Yue-Sheng Li, Haichun Huang
Abstract: An arrangement at a stoma bag of the type used by persons or animals with a colostoma, including a flexible bag (flexibag) and a ring fastener/magazine ring, where the ring fastener/magazine ring is designed to be connected to a stoma plate, and where, in its initial position, the entire flexibag is located in or in close proximity to the ring fastener/magazine ring.